This article is part of the supplement: Basic science, rationale, background and future of denosumab: a RANK ligand inhibitor

Highly Accessed Review

Erosive arthritis

Georg Schett

Arthritis Research & Therapy 2007, 9(Suppl 1):S2 doi:10.1186/ar2166

No comments have yet been made on this article.

Post a comment